From the FDA Drug Label
The recommended dose is 2 pump actuations on each painful knee, 2 times a day. For relief of the pain of osteoarthritis (OA) of the knee(s), the recommended dose is 40 mg of diclofenac sodium (2 pump actuations) on each painful knee, 2 times a day.
The FDA-approved dosing for Voltaren Gel (diclofenac sodium topical solution) is specifically for knee pain due to osteoarthritis, with a recommended dose of 40 mg (2 pump actuations) per knee, 2 times a day.
- There is no information provided for shoulder or back pain.
- The dosing instructions are to apply the gel to clean, dry skin, and to wash hands completely after administering the product 1.
From the Research
Voltaren gel (diclofenac sodium) is effective for treating knee, shoulder, and back pain by reducing inflammation and pain when applied directly to the affected area, with a recommended dose of 4 grams applied to the affected area four times daily. The application of Voltaren gel is based on the affected area, with the following guidelines:
- For knee and ankle pain, apply 4 grams of gel to the affected area four times daily (maximum 16 grams per joint daily) 2.
- For hand, wrist, or elbow pain, use 2 grams per joint four times daily (maximum 8 grams per joint daily).
- For shoulder and back pain, apply 4 grams to the affected area four times daily. To apply, squeeze the prescribed amount onto your hand or directly onto the painful area, then gently rub it in until absorbed. Wash your hands after application unless treating hand pain. Voltaren works by blocking prostaglandins that cause pain and inflammation. Some key points to consider when using Voltaren gel include:
- Side effects may include skin irritation, and you should avoid sun exposure on treated areas.
- Don't use Voltaren gel with oral NSAIDs without medical advice, and don't apply to broken or irritated skin.
- If pain persists beyond 7 days or worsens, consult your healthcare provider. According to a recent study, topical diclofenac 70-81 mg/day seems to be effective and generally safer because of reduced systemic exposure and lower dose, and should be considered as first line pharmacological treatment for knee osteoarthritis 2.